The Efficacy of Acamprosate and Naltrexone in the Treatment of Alcohol Dependence: A Relative Benefits Analysis of Randomized Controlled Trials

REFERENCES

• Gual A, Lehert P H. Acamprosate during and after acute alcohol withdrawal. Alcohol and Alcoholism 2001; 36(5)413–417
   PubMed Web of Science ®Google Scholar
• Sinclair J D. Evidence about the use of naltrexone and four different ways of using it in the treatment of alcoholism. Alcohol and Alcoholism 2001; 36(1)2–10
   PubMed Web of Science ®Google Scholar
• Rubio G, Jiménez-Arriero M A, Ponce G, Palomo T. Naltrexone versus acamprosate: One year follow up of alcohol dependent treatment. Alcohol and Alcoholism 2001; 36(5)419–425
   PubMed Web of Science ®Google Scholar
• DeWildt W AJM, Schippers G M, Van Den Brink W, Potgieter A S, Deckers F, Bets D. Does psychosocial treatment enhance the efficacy of acamprosate in patients with alcohol problems?. Alcohol and Alcoholism 2002; 37(4)375–382
   PubMed Web of Science ®Google Scholar
• Vaughn M G, Howard M O. Integrated psychosocial and opioid-antagonist treatment for alcohol dependence: A systematic review of controlled evaluations. Social Work Research 2004; 18(1)41–53
   Web of Science ®Google Scholar
• Volpicelli J R, Clay K L, Watson N T, O'Brien C P. Naltrexone in the treatment of alcoholism: Predicting response to naltrexone. J Clin Psychiatry 1995; 56(7)39–44
   PubMed Web of Science ®Google Scholar
• Anton R F, Monk D H, Waid R, Latham P K, Malcolm R J, Dias J K. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: Results of a placebo-controlled trial. Am J Psychiatry 1999; 56(11)1758–1764
   Google Scholar
• Mason B J, Goodman A M, Chabac S, Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial. The role of patient motivation. J Psychiatric Res 2006; 40: 383–393
   PubMed Web of Science ®Google Scholar
• O'Malley S S, Jaffe A J, Rode S, Rounsaville B J. Experience a “slip” among alcoholics treated with naltrexone or placebo. Am J Psychiatry 1996; 153(2)281–283
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders (DSM IV TR). APA, Washington, DC 2000
   Google Scholar
• Swift R M. Medications and alcohol cravings. Alcohol Research and Health 1999; 23(3)207–213
   Web of Science ®Google Scholar
• Hedges L V, Olkin I. Statistical Methods for Meta-Analysis. Academic Press, New York 1985
   Google Scholar
• Kraemer H C, Andrew G. A non-parametric technique for meta-analysis effect size calculation. Psychological Bulletin 1982; 91: 404–412
   Web of Science ®Google Scholar
• Chalmers T C, Smith H, Blackburn B, Silverman B, Schroeder B, Reitman D, et al. A method for assessing the quality of a randomized control trial. Controlled Clinical Trials 1981; 2: 31–49
   PubMedGoogle Scholar
• Moyer A, Finney J W, Swearinger C E. Methodological characteristics and quality of alcohol treatment outcome studies, 1970–1998; An expanded evaluation. Addiction 2002; 97: 253–263
   PubMed Web of Science ®Google Scholar
• Paille F M, Guelfi J D, Perkins A C, Royer R J, Steru L, Parot P. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol and Alcoholism 1995; 30: 239–247
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986; 7: 177–188
   PubMedGoogle Scholar
• Pelc I, Le Bon O, Verbanck P, Lehert P H, Opsomer L. Calcium acetyl homotaurinate for maintaining abstinence in weaned alcoholic patients: a placebo-controlled double-blind multi-centre study. Novel Pharmacological Interventions for Alcoholism 1992; 348–352
   Google Scholar
• Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K, Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. British Journal of Psychiatry 1997; 171: 73–77
   PubMed Web of Science ®Google Scholar
• Besson J, Aeby F, Kasas A, Lehert P, Potgieter A. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: A controlled study. Alcoholism: Clinical and Experimental Research 1998; 22: 573–579
   PubMed Web of Science ®Google Scholar
• Kiritzé-Topor P, Haus D, Rosenzweig C, Comte S, Paille F, Lehert P. A pragmatic trial of acamprosate in the treatment of alcohol-dependence in primary care. Alcohol and Alcoholism 2004; 39(6)520–527
   PubMed Web of Science ®Google Scholar
• Namkoong K, Lee B O, Lee P G, Choi M J, Lee E. Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcohol and Alcoholism 2003; 38: 135–141
   PubMed Web of Science ®Google Scholar
• Poldrugo F, Haeger D, Comte S, Walburg J, Palmer A. A critical review of pharmacoeconomic studies of acamprosate. Alcohol & Alcoholism 1997; 40(5)422–430
   Web of Science ®Google Scholar
• Baltieri D A, Andrade A G. Efficacy of acamprosate in the treatment of alcohol-dependent outpatients. Revista Brasileira de Psiquiatria 2003; 25: 1516–1525
   Google Scholar
• Kiefer F, Andersohn F, Otte C, Wolf K, Jahn H, Wiedemann K. Long-term effects of pharmacotherapy on relapse prevention in alcohol dependence. Acta Neuropsychiatrica 2004; 16: 233–244
   PubMed Web of Science ®Google Scholar
• Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: A double-blind placebo-controlled study. Archives of General Psychiatry 2003; 60(1)92–99
   PubMed Web of Science ®Google Scholar
• Lhuintre J P, Daoust M, Moore N D, Chretien P, Saligaut C, Tran G, Bosimare F, Hillemand B. Ability of calcium bis acetyl homotaurinate, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet 1985; 1: 1014–1016
   PubMed Web of Science ®Google Scholar
• Lhuintre J P, Moore N, Tran G, Steru L, Langrenon S, Daoust M, Parot P, Ladure P, Libert C, Boismare F. Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol and Alcoholism 1990; 25: 613–622
   PubMed Web of Science ®Google Scholar
• Niederhofer H, Staffen W. Acamprosate and its efficacy in treating alcohol-dependent adolescents. European Child & Adolescent Psychiatry 2003; 12: 144–148
   PubMed Web of Science ®Google Scholar
• Roussaux J P, Hersh D. Does acamprosate diminish the appetite for alcohol in weaned alcoholics?. Journal de Pharmacie de Belgique 1996; 51: 65–68
   PubMedGoogle Scholar
• Tempesta E, Janiri L, Bignamini A, Chabac S, Potgiete A. Acamprosate and relapse prevention in the treatment of alcohol dependence. Alcohol and Alcoholism 2000; 35(2)202–209
   PubMed Web of Science ®Google Scholar
• Chick J, Anton R, Checinski K, Croop R, Drummond D C, Farmer R, et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone. Alcohol and Alcoholism 2000; 35(6)587–593
   PubMed Web of Science ®Google Scholar
• Volpicelli J R, Clay K L, Watson N T, O'Brien C P. Naltrexone in the treatment of alcoholism: Predicting response to naltrexone. Journal of Clinical Psychiatry 1995; 56(7)39–44
   PubMed Web of Science ®Google Scholar
• Geerlings P J, Ansoms C, Van den Brink W. Acamprosate and prevention of relapse in alcoholics. Results of a randomized, placebo-controlled, double-blind study in out-patient alcoholics in the Netherlands, Belgium and Luxembourg. European Addiction Research 1997; 3: 129–137
   Web of Science ®Google Scholar
• Ladewig D, Knecht T, Lehert P. Acamprosate – a stabilizing factor in long-term withdrawal of alcoholic patients. Therapeutische Umschau 1993; 50: 182–188
   PubMedGoogle Scholar
• Barrias J A, Chabac S, Ferreira L, Fonte A, Potgieter A S, Teixeira de Sousa E. Acamprosate: Multicenter Portuguese efficacy and tolerance evaluation study. Psiquiatr Clin 1997; 18: 149–160
   Google Scholar
• Heinãlã P, Alho H, Kiianmaa K, Lönnqvist J, Kuoppasalmi K, Sinclair J D. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: A factorial double-blind placebo controlled trial. Journal of Clinical Psychopharmacology 2001; 21(3)287–292
   PubMed Web of Science ®Google Scholar
• Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Archives of General Psychiatry 1996; 53: 673–680
   PubMed Web of Science ®Google Scholar
• Hersh D, Van Kirk J R, Kranzler H R. Naltrexone treatment of comorbid alcohol and cocaine use disorders. Psychopharmacology (Berlin) 1998; 139: 44–52
   PubMed Web of Science ®Google Scholar
• Krystal J H, Cramer J A, Krol W F, Kirk G F, Rosenheck R A. Veterans Affairs Naltrexone Cooperative Study 425 Group. Naltrexone in the treatment of alcohol dependence. New England Journal of Medicine 2001; 345(24)1734–1739
   PubMed Web of Science ®Google Scholar
• Latt N C, Jurd S, Houseman J, Wutzke S E. Naltrexone in alcohol dependence: A randomized clinical trial of effectiveness in a standard clinical setting. Medical Journal of Australia 2002; 176(11)530–534
   PubMed Web of Science ®Google Scholar
• Monti P M, Rohsenow D J, Swift R M, Gulliver S B, Colby S M, Mueller T I, et al. Naltrexone and cue exposure with coping and communication skills training for alcoholics: Treatment process and one-year outcomes. Alcoholism: Clinical and Experimental Research 2001; 25: 1634–1647
   PubMed Web of Science ®Google Scholar
• Morris P L, Hopwood M, Whelan G, Gardiner J, Drummond E. Naltrexone for alcohol dependence: A randomized controlled trial. Addiction 2001; 96(11)1656–1573
   Web of Science ®Google Scholar
• Guardia J, Caso C, Arias F, Gual A, Sanahuja J, Ramirez M, Mengual I, Gonzalvo B, Segura J, Trujols J, Casas M. A. double-blind, placebo controlled study of naltrexone in the treatment of alcohol-dependence disorder: Results from a multicenter clinical trial. Alcoholism: Clinical and Experimental Research 2002; 26: 1381–1387
   PubMed Web of Science ®Google Scholar
• Kranzler H R, Modesto-Lowe V, Van Kirk J, Jr. Naltrexone vs. nefazodone for treatment of alcohol dependence: A placebo-controlled trial. Neuropsychopharmacology 2000; 22(5)493–503
   PubMed Web of Science ®Google Scholar
• Oslin E, Liberto J G, O'Brien J, Krois S, Norbeck J. Naltrexone as an adjunctive treatment for older patients with alcohol dependence. American Journal of Geriatric Psychiatry 1997; 5: 324–332
   PubMed Web of Science ®Google Scholar
• Volpicelli J R, Rhines J S, Volpicelli L A, Alterman A I, O'Brien C P. Naltrexone and alcohol dependence. Role of subject compliance. Archives of General Psychiatry 1997; 54: 737–742
   PubMed Web of Science ®Google Scholar
• Gastpar M, Bonnet U, Boning J, Mann K, Schmidt L G, Soyka M, et al. Lack of efficacy of naltrexone in the prevention of alcohol relapse: Results from a German multicenter study. Journal of Clinical Psychopharmacology 2002; 22(6)92–98
   PubMed Web of Science ®Google Scholar
• Lee A, Tan S, Lim D, Winslow R M, Wong K E, Allen J. Naltrexone in the treatment of male alcoholics-an effectiveness study in Singapore. Drug Alcohol Review 2001; 20(2)1993–1999
   Web of Science ®Google Scholar
• O'Malley S S, Jaffe A J, Chang G, Schottenfeld R S, Meyer R E. Rounsaville Naltrexone and coping skills therapy for alcohol dependence: A controlled study. Archives of General Psychiatry 1992; 49: 881–887
   PubMed Web of Science ®Google Scholar
• Kranzler H R, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: A meta-analysis. Alcoholism: Clinical and Experimental Research 2001; 25: 1335–1341
   PubMed Web of Science ®Google Scholar
• Streeton C, Whelan G. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: A meta-analysis of randomized controlled trials. Alcohol and Alcoholism 2001; 36(6)544–552
   PubMed Web of Science ®Google Scholar
• Landabaso M A, Iraurgi I, Sanz J, Calle R, Ruiz de Apodaka J, Jimenez-Lerma J M, et al. Naltrexone in the treatment of alcoholism: Two-year follow up results. European Psychiatry 1999; 13: 97–105
   Web of Science ®Google Scholar
• Whitworth A B, Fischer F, Lesch O M, Nimmerrichter A, Oberbauer H, Platz, et al. Comparison of acamprosate and placebo in long-term treatment. The Lancet 1996; 347(9013)1438–1442
   PubMed Web of Science ®Google Scholar